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Physiological studies and preliminary behavioral screening with animals 
have indicated that syrosingopinel (carbethoxysyringoyl methylreserpate) , 
a reserpine derivative, is a hypotensive drug with little or no “tranquil- 
izing” action. The present study was designed to explore and check on 
these findings, as related to adverse behavioral effects, in a controlled ex- 
periment with human patients. The Driver Trainer and Ortho-Rater, 
used in previous experiments (Marquis et al., 1957; Kelly et al., 1958b) 
to test for possible adverse behavioral effects of psychoactive drugs were 
employed to test the effects of syrosingopine on psychomotor and visual 
functions. Simple tests of attention, alertness, tempo, and mood were 
used to explore some of the other common modes of action of a psycho- 
active drug. 
METHOD 
A counterbalanced double-blind design, in which all patients acted as 
their own controls, was employed as follows: Each patient was given three 
drug treatments: (a) 1 mg syrosingopine; (b) 5 mg syrosingopine; and 
(c) a placebo. Each treatment was taken daily for a period of 28 days. 
All tablets were identical in taste and appearance. Tablets were packaged 
in envelopes and dispensed daily, between 7:00 and 8:00 A.M., to each 
patient, who took the tablet in the presence of one of the testers. Neither 
tester nor patient was aware of the identity of any of the tablets. All six 
possible orderings of the three drugs were followed for an equal number 
of patients, so that ordering effects would be counterbalanced and can- 
celed out across the entire group. The patients were prisoners at the 
State Prison of Southern Michigan and all served as paid volunteers. 
1 SingoserpB, Ciba Pharmaceutical Products, Inc., Summit, New Jersey. 
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The prison routine allowed us to exercise unusually close supervision 
over the day-to-day details of the experiment. All patients reported at the 
same time each morning for their daily tablets. Behavioral testing was 
done at the same time of day for each patient at the termination of each 
treatment. All patients were also given a pre-experiment training and 
practice session. 
Thirty-two men completed the experiment. One man asked to be 
dropped immediately before the first testing session, apparently because 
of fear that he would not perform well on the tests, and was replaced by 
another patient. Two men were dropped because they did not report at 
the time assigned for testing and it was not possible to reschedule them. 
Two men were not used in the data analysis because of their difficulty in 
reading and observing test materials: one because of broken glasses, the 
other because of illiteracy. All other patients completed the entire course 
of treatment with no ill effects. 
Thirty-five objectively measured variables were scored from the various 
aspects of the patient’s performance on ten different tests. These tests, 
together with scores obtained on each, are described below. 
A. Driver Test ( 7 scores). The American Automobile Association’s 
“Auto Trainer” was used to test compIex psychomotor skiIIs of the sort 
used while driving an automobile. The patient operates the trainer by 
working the controls of a conventional shift automobile. A treadmill-like 
belt about 10 feet long, painted to resemble a winding road, extends in 
front of the control unit. A model car, connected to the steering wheel 
and operated by the patient, rests on the belt. The patient’s job is to keep 
the car on the road and to brake the car whenever a red light appears. 
For a more complete description of this apparatus, see Marquis et al. 
(1957). 
Patients were given trials as follows: twenty revolutions of the belt at 
a fixed low speed, twenty at a fixed high speed, and twenty at a speed con- 
trolled by the patient. Six reaction-time determinations were interspersed 
irregularly through the first two trials. 
Accuracy, or proficiency, of driving in this situation is measured in 
terms of the patient’s ability to keep the car on the road. Three accuracy 
scores were obtained: at the fixed low speed, at the fixed high speed, and 
at the variable patient-controlled speed. A “speed” score, the time re- 
quired for the trial when the patient was controlling his own speed, was 
also obtained. During this phase of the test the patient was asked to 
drive as rapidly and as accurately as he could. -4 derived score was also 
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computed by taking the ratio of the difference between the accuracy score 
at low fixed speed and the accuracy score at patient-controlled speed, and 
dividing by the time score. This speed:accuracy ratio, which indicated 
the degree to which speed was sacrificed for accuracy, or vice versa, may 
be interpreted as a measure of judgment. The seven scores on the Driver 
Test thus included three accuracy scores, one speed score, one judgment 
score, and two reaction-time scores. 
B. Vision Tests (7 scores). Tests of the various components of vision 
that might be affected by psychoactive drugs were conducted on the 
Bausch and Lomb master model Ortho-Rater, an instrument designed to 
control illumination, distance, and presentation of stimuli used to test the 
various functions of vision (Marquis et a,?., 1957). 
Acuity was determined for both far and near vision; depth perception 
was determined for distant vision only. Vertical and lateral phorias for 
both near and far vision were also measured. Phoria scores indicate the 
relative posture or muscular balance of the eyes in relation to each other 
under conditions of controlled accommodation. A perfect vertical phoria 
score indicates that the horizontal midline in both the right and left visual 
fields is in the same axis. A perfect lateral phoria score indicates the same 
for the vertical midline. 
C. Bourdon Alternate Coding Test (4 scores). This test, which de- 
pends upon rigidity and attention as well as psychomotor skills (Uhr 
et al., 1959), consists of rows of dots arranged in units of 3, 4, or 5 
dots. The patient is instructed to draw a vertical line through the three- 
dot unit, a horizontal line through the four-dot unit, and no line through 
the five-dot unit. He is scored for number correct as well as errors for a 
45second test period. He is then told to change his coding method; to 
draw no line through the three-dot unit, a vertical line through the four- 
dot unit, and a horizontal line through the five-dot unit, and given a 45- 
second test period. A third 4S-second test period is then run with instruc- 
tions to follow the first coding procedure for the first line, the second 
coding procedure for the second line, and to continue to alternate back 
and forth at the beginning of each new line. Number correct and errors 
were scored separately, for the first two periods combined, and for the 
third change-set period. 
D. Continuous Attention Test (2 scores). This test consisted of three 
pages, each containing 100 lines of ten random letter groups, in half of 
which an “E” was embedded. The patient was instructed to write a plus 
next to a line which contained an “E” and a zero next to a line that did 
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not. A metronome was set to beat at the rate of one per second, and the 
patient was told to work at this steady rate, doing one line per second. 
Total correct and number of errors over the standard five-minute test 
were scored separately. 
E. O’Connor Finger Dexterity Test (1 score). In this task, which 
calls for quick, fine, finger manipulations, the patient is asked to insert 
l/16-inch brass pins, in groups of threes, into l/4-inch holes, working as 
fast as he can. The number of pins correctly inserted in a l-minute test 
period is recorded as the patient’s score. 
F. Short-Term Memory and Attention Span (1 score). Digit span 
forward was tested and scored, according to standard Wechsler-Bellevue 
procedures (Wechsler, 1944). This test has been shown by Kornetsky 
et al. (1957) to be sensitive to the effects of phenothiazines and barbitu- 
rates, whereas it does not appear to be affected by milder psychoactive 
drugs, such as meprobamate (Uhr et al., 1959). 
G. Tapping Rate (1 score). In this test the patient is asked to tap, 
as rapidly as he can, using a standard telegraph key. He is given two 
30-second test periods from which the single combined score of number 
of taps is obtained. 
H. Preferred Tempo (1 score). An electric metronome is turned on 
and varied in tempo by the experimenter. The patient is then asked to 
set the metronome to the tempo he prefers. 
I. Semantic Differential Test (3 scores). A modified version of Os- 
good’s Semantic Differential (an empirically derived form designed to 
measure how a person perceives himself, Osgood, 1952) was used to get 
determinations on three independent aspects of patients’ feelings while 
under the influence of the drug treatments: ( 1) feelings of activity, (2) 
feelings of potency, and (3) self-evaluation. 
I. Self-Report Check List (8 scores). The patient made quick 
ratings on a seven-point scale as to how he felt on each of eight variables 
that were related to possible drug effects, (Kelly et al., 1958b). These 
included three physical feelings: good, tense, and alert; and five psycho- 
logical feelings: confident, calm, good, tense, and lucky. 
RESULTS 
Tables 1 and 2 present the results obtained on the thirty-five variables 
scored from the objective test battery, in terms of differences between the 
effects of the different drug treatments. Table 1 presents the variables 
538 JAMES G. MILLER AND LEONARD UHR 
TABLE 1 
MEAN DIFFERENCES IN PERFORMANCE ON BEHAVIORAL TESTS AMONG THE 
THREE COMBINATIONS OF DRUG TREATMENTS 
Combination of Drug Treatments 
Variable 
Placebo Placebo 1 w3 
YS YB “S 
1 mg syrosingopine 5 mg syrosingopine 5 mg. syrosingopine 
Mean Standard Meall Standard Mean Standard 
differencea exo$’ difference” error difference errorb 
A. Driver test 
Slow speed: 
1. Accuracy 
2. Reaction time 
Fast speed: 
3. Accuracy 
4. Reaction time 
Variable: 
5. Accuracy 
6. Total time 
7. Judgment 




Phoria (vertical) : 
10. Near 
11. Far 











3.6 4.96 4.0 4.13 -7.6 5.33 
1.9 1.98 -0.4 1.70 -2.3 1.66 
0.7 6.08 4.8 4.6 1 4.1 5.56 
1.4 1.23 1.9 1.66 0.5 1.51 
0.0 5.42 6.4 7.16 6.4 6.09 
2.0 7.0 -5.0 9.1 -7.0 6.1 





2.7 2 3.0 





1.9 1 I.7 




3.4 7 3.6 
2.9 7 2.3** 




































D. Contimoss atteention 
19. Correct 1.7 
20. Marked wrong 2 
E. Finger dexterity 
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TABLE 1 (Continued) 
MEAN DIFFERENCES IN PERFORMANCE ON BEHAVIORAL TESTS AMONG THE 
THREE COMBINATIONS OF DRUG TREATMENTS 
Combination of Drug Treatments 
Placeboa Placeboa lW&Q 
“8 “9 “9 
1 mg  syrosingopine 5 mg  syrosingopine 5 mg  syrosingopine 
MeaLl Standard MeXI Standard Meall Standard 
Variable differencea ermrh differencea error difference’ errorb 
F. Digit span 
22. Remembered 
number 0.1 1.8 0.1 1.6 0 2.1 
G. Tapping rate 
23. Number completed 1.7 5.24 3.2 4.88 1.5 5.10 
H. Preferred tempo 
24. Beats/minute 3.9 4.71 0.1 5.34 -3.8 3.24 
a No sign indicates first-listed treatment gave better performance. Minus sign in- 
dicates second-listed treatment gave better performance. 
h Single asterisk: difference significant beycnd the 0.05 level of confidence. Double 
asterisk: difference significant beyond the 0.01 level of confidence. 
that measured overt behavior; Table 2 presents the variables that were 
scored from self-reports. 
The three treatments (placebo, 1 mg syrosingopine, and 5 mg syro- 
singopine) allowed for three different comparisons between treatments: 
( 1) placebo vs 1 mg syrosingopine, (2) placebo vs 5 mg syrosingopine, 
and (3) 1 mg vs 5 mg syrosingopine. Means, sigmas (i.e., standard 
deviations), and correlations were computed for all three treatments. 
Then the mean differences and the standard error of these differences 
(which gives a measure of their random fluctuations and thus allows for 
a test of statistical significance), were computed for all three combina- 
tions of tablet treatments for each of the thirty-five variables scored. The 
critical ratio of the difference was then computed for the evaluation of 
the significance of each difference. 
For the sake of clarity in presentation, only the mean difference and 
the standard error of this difference are presented in the tables. Those 
differences whose critical ratios achieved significance are identified by a 
single asterisk for significance beyond the 5 5% level and a double asterisk 
for significance beyond the 1 7% level of probability. (Means, sigmas, 
correlations, and critical ratios for all the variables can be obtained from 
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the authors.) The sign of the mean difference indicates which of the two 
treatments being compared led to the more favorable performance. 
TABLE z 
MEAN DIFFERENCES IN SELF-REPORTS AMONG THE THREE COMBINATIONS 
OF DRUG TREATMENTS 




1 mg  syrosingopine 5 mgsyrasingopine 
MeatI Standard Meall Standard 
ditTerence’ error difference’ er109 
1 w 
“9 
5 mg  syrosingopine 
Meall Stsndard 
differencea error 
1. Semantic dijerential 
1. Activity 5 7.4 2 6.1 -3 5.3 
2. Potency 3 5.4 8 5.3 5 5.4 
3. Self-evaluation 
J. Check list 
How feel physically: 
4. Good 1 2.2 0 1.3 -1 2.4 
5. Tense 4 3.6 1 3.1 5 3.8 
6. Alert 3 3.2 1 2.8 -2 2.8 
How feel psycho- 
logically: 
3. Confident -1 2.9 -1 2.7 0 3.4 
8. Calm --5 3.3 0 4.3 5 4.4 
9. Good -5 2.9 -5 2.4* 0 3.2 
10. Tense -3 4.2 1 4.0 4 4.5 
11. Lucky 1 3.3 1 2.5 0 3.1 
Q No sign indicates first-listed treatment gave better performance. Minus sign in- 
dicates second-listed treatment gave better performance. 
b Asterisk: difference significant beyond the 0.05 level of confidence. 
When a relatively large number of variables are tested simultaneously 
for the effects of different drug treatments, and several combinations of 
treatments are examined, chance effects alone will lead to a certain num- 
ber of statistically significant results. The conventional 5 ‘$ and 1 yO 
probability levels, which are used in the present study, are set so that 
chance alone would lead to the achieving of these levels 5 s and 1 s 
of the time, respectively. With three combinations of thirty-five variables, 
we would thus expect, by chance alone, at least five significances at the 
5 % level, one of which would also be significant at the 1 % level. It thus 
seems quite likely that the three contrasts found to be significant at the 
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5 5% level, one of which was significant at the 1 5% level, were all chance 
occurrences. Syrosingopine, chronically administered in both I-mg and 
S-mg daily doses, does not have any adverse behavioral effects as tested 
on the present battery of driving, vision, attention, and self-report tasks. 
DISCUSSION 
The battery of tests used in this study was chosen to elicit and measure 
a wide variety of behavior, covering the different functions of a normal 
human being who must continue his day-to-day activities while under pro- 
longed drug treatment. The simple and complex psychomotor tests used 
here involve several motor performance factors, such as reaction time, 
vertical and horizontal tracking, fine muscle dexterity and steadiness, both 
singly and combined into complex patterns on the driver trainer. These 
tests, along with the check on the basic components of visual perception, 
would seem to assess the major behaviors that must continue at a normal 
level under outpatient treatment. 
Several studies give indications of the magnitude of effects to be ex- 
pected from these tests from a variety of different drugs. Marquis et al. 
( 1957) found small improvements in performance under the effects of 
d-amphetamine sulfate, small decrements under the effects of a single 
shot of alcohol, and no effects from meprobamate as compared with 
placebo-all treatments given once to normal subjects. Kelly et al. (1958a, 
b), examining the chronic effects of meprobamate and prochlorperazine on 
the performance of normal subjects on an especially large battery of be- 
havioral tests, found a number of individual statistically significant effects, 
possibly indicating the sensitivity of the tests to these drugs, but con- 
cluded that, because of the large number of tests of significance that were 
conducted, the results of the study as a whole did not appear to indicate 
more than chance effects. Uhr et al. (in press), testing the chronic effects 
of meprobamate and of a bromide on the behavior of anxious subjects, 
found several significant effects from each of these treatments as com- 
pared with placebo. 
Kristofferson and Cormack (in press), using a driving test and ex- 
perimental procedure closely modeled after the above-mentioned studies, 
found several effects from small doses of alcohol but none from Quiactin. 
Loomis and West (1958b) and Melander (1957) each used laboratory 
simulated driving tests, each somewhat different in detail. Melander 
found significant effects from amobarbital and no effects from mepro- 
bamate, in contrast to Loomis and West’s findings of decrements in per- 
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formance from meprobamate as well as from chlorpromazine and seco- 
barbital, but none from phenaglycodol. In a related study, Loomis and 
West (1958a) found their driving test sensitive to small and to differential 
doses of alcohol. Kornetsky et al. ( 1957, 1959), using simple tests of 
psychomotor performance, found a number of significant effects of several 
dose levels of chlorpromazine and secobarbital. 
The tests of attention and simple intellectual functioning (Bourdon, 
digit span) have given similar indications, in previous experiments, of 
some sensitivity to mild drugs whose effects should be on the order of the 
treatment tested in this study. The studies by KelIy et al. (1958a, b), 
Uhr et al. (in press), and Kornetsky et al. (1957, 1959), plus unpublished 
pretest studies conducted with a view to choosing batteries of tests that 
might be sensitive to drug effects, give indications of occasional slight 
decrements in performance, probably indicative of some slowing and re- 
laxing of attention and alertness. 
Finally, self-report measures of anxiety and feelings have given in- 
dications of slight drug effects in decreasing anxiety and activity level, 
and in increasing such feelings as confidence, calmness, and alertness, but 
often depend upon the type of subject used. Thus Uhr et al. found the 
most clear-cut effect of drugs on their population of anxiety neurotics, as 
opposed to much smaller and somewhat conflicting effects found by Kelly 
et al. (1958a, b) on their population of normal studies. Heller et al. (1957) 
found self-reported effects from meprobamate upon one type of patient 
(anxious) but not upon another (hysteric). 
These studies should help the reader in establishing a rough metric of 
drug effects that might be expected upon the present battery of tests. In 
general, each test, at some time or another, has been found sensitive to a 
relatively mild psychoactive drug, and has therefore been chosen as among 
the best available for a check-out of behavioral effects in an assessment of 
a new drug. The state of this new science still does not present the ex- 
perimenter with a ready choice of tests for which well-confirmed state- 
ments as to the effects of varying amounts of drugs of varying potencies 
can be made. Probably a weaker statement can be made with somewhat 
greater confidence: that effects great enough to be of danger to normal 
functioning would be detected by these tests. 
SUMMARY 
Thirty-two male patients were tested for the chronic effects of treatment under 
two dose levels of syrosingopine upon objectively measured behavior and subjective 
reactions. All patients completed three Z&day treatment periods: (a) 1 mg syro- 
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singopine, (b) 5 mg syrosingopine, and (c) matching placebo, given daily, and thus 
served as their own controls. Double-blind administration was effected, and ordering 
of treatments was counter-balanced across patients, to cancel out any practice effects. 
At the end of each treatment period, each patient was tested on the battery of 
behavioral tests. 
Thirty-five variables were scored from the test battery and examined statistically 
for the significance of the differences between all combinations of treatments: (1) 
placebo vs 1 mg syrosingopine, (2) placebo vs 5 m, 0 syrosingopine, and (3) 1 mg vs 
5 mg syrosingopine. Only three critical ratios were significant beyond the S % level, 
when, because of the large number of tests of significance made, five would be ex- 
pected by chance alone. It therefore seems clear that test behavior was not sig- 
nificantly affected by the drug, in either I-mg or S-mg daily doses, as compared with 
a placebo. Thus, as tested in this experiment, the chronic administration of syro- 
singopine, both in low and in high doses, gave no adverse behavioral effects. 
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